End-of-day quote
NSE India S.E.
23:00:00 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
377.6
INR
|
-0.32%
|
|
-1.73%
|
+19.98%
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
39,702
|
15,352
|
30,394
|
-
|
-
|
Enterprise Value (EV)
1 |
39,702
|
15,352
|
30,394
|
30,394
|
30,394
|
P/E ratio
|
26.2
x
|
17.1
x
|
26.5
x
|
20.4
x
|
16.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
3.33
x
|
5.41
x
|
4.43
x
|
3.63
x
|
EV / Revenue
|
-
|
3.33
x
|
5.41
x
|
4.43
x
|
3.63
x
|
EV / EBITDA
|
-
|
11.9
x
|
18.7
x
|
15.3
x
|
12.5
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
80,483
|
80,483
|
80,483
|
-
|
-
|
Reference price
2 |
493.3
|
190.8
|
378.8
|
378.8
|
378.8
|
Announcement Date
|
20/05/22
|
26/05/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
4,609
|
5,617
|
6,864
|
8,376
|
EBITDA
1 |
-
|
1,289
|
1,628
|
1,991
|
2,429
|
EBIT
1 |
-
|
-
|
1,469
|
1,865
|
2,276
|
Operating Margin
|
-
|
-
|
26.15%
|
27.17%
|
27.17%
|
Earnings before Tax (EBT)
1 |
-
|
1,235
|
1,565
|
1,948
|
2,357
|
Net income
1 |
1,518
|
898.6
|
1,148
|
1,500
|
1,846
|
Net margin
|
-
|
19.49%
|
20.44%
|
21.85%
|
22.04%
|
EPS
2 |
18.86
|
11.16
|
14.30
|
18.60
|
22.90
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/05/22
|
26/05/23
|
-
|
-
|
-
|
Fiscal Period: March |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
1,014
|
1,122
|
-
|
1,423
|
1,320
|
1,345
|
1,211
|
1,495
|
EBITDA
1 |
312.4
|
515.4
|
-
|
550.4
|
444.9
|
400
|
341
|
453
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
95.18
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
1.180
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/08/22
|
10/11/22
|
14/02/23
|
26/05/23
|
03/08/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
13.7%
|
14.2%
|
15.7%
|
16.3%
|
ROA (Net income/ Total Assets)
|
-
|
11.6%
|
12.1%
|
13.5%
|
14%
|
Assets
1 |
-
|
7,775
|
9,488
|
11,111
|
13,186
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/05/22
|
26/05/23
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +19.98% | 365M | | +33.18% | 709B | | +30.77% | 595B | | -2.09% | 367B | | +20.14% | 334B | | +5.32% | 289B | | +14.77% | 239B | | +9.13% | 211B | | -3.97% | 203B | | +9.06% | 171B |
Other Pharmaceuticals
|